Paeonol-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEPaeonolCat.No.:HY-N0159CASNo.:552-41-0分⼦式:C₉H₁₀O₃分⼦量:166.17作⽤靶点:MonoamineOxidase;Autophagy作⽤通路:NeuronalSignaling;Autophagy储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验Ethanol:50mg/mL(300.90mM;Needultrasonic)DMSO:≥38mg/mL(228.68mM)H2O:1mg/mL(6.02mM;Needultrasonic)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制备储备液1mM6.0179mL30.0897mL60.1793mL5mM1.2036mL6.0179mL12.0359mL10mM0.6018mL3.0090mL6.0179mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(15.04mM);Suspendedsolution2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(15.04mM);Clearsolution3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(15.04mM);Clearsolution4.请依序添加每种溶剂：10%EtOH>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(15.04mM);Clearsolution5.请依序添加每种溶剂：10%EtOH>>90%cornoilSolubility:≥2.5mg/mL(15.04mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性Paeonol牡丹根的活性提取物，Paeonol抑制MAO-A和MAO-B，IC50分别为54.6μM和42.5μM。IC50&TargetIC50:42.5μM(MAO-B),54.6μM(MAO-A)[1]体外研究PaeonolisfoundtobeinhibitoryagainstMAOAinadose-dependentmannerwithIC50valueof54.6μM.PaeonolisshowntoinhibitMAO-Binadose-dependentmannerwiththeIC50of42.5μM.ForPaeonol,theKiisestimatedtobe51.1μM.TheinhibitionofPaeonolonMAOBisofcompetitivetypewithKivalueof38.2μM[1].体内研究The200mg/kgPaeonol+I/Rgroup[AN/V(%):7.6±2.2,p[2].PROTOCOLAnimalMice[2]Administration[2]MaleWistarrats(180-220g,averageageof8week)arerandomlydividedintofourgroups:(1)shamgroup,thoracotomywithoutleftanteriordescendingcoronaryartery(LAD)occlusionorPaeonolpretreatment;(2)I/Rgroup,LADocclusion(ischemia)for4hfollowedbyreperfusionfor8h;(3)Paeonol(100mg/kg)+I/Rgroup,oraladministrationof100mg/kgPaeonol(1mL/kg)for7daysusingaintragastrictubepriortoI/Rprocedure;(4)Paeonol(200mg/kg)+I/Rgroup,oraladministrationof200mg/kgPaeonol(1mL/kg)for7daysusingaintragastrictubepriortoI/Rprocedure.Inaddition,ratsintheshamandI/RgroupsreceivedadosageofDMSOequaltothatwithwhichthePaeonolwasdissolvedinfortheothertwogroups.DMSOwasalsoadministeredintragastricallyfor7consecutivedays.Aminimumofeightratswereassignedtoeachgroup.AnischemiagroupwithoutreperfusionisnotincludedsinceourpresentstudymainlyfocusesontheeffectofPaeonolonthecardiacinjuriesafterreperfusion,whichiscloselyrelatedtothereal-worldsituationofno-reflowaftercoronaryrevascularization.However,futurestudiesmayincludeagroupsubjectedonlyto4hofischemiatodifferentiate,intermsofdamagetothecardiacfunction,whichwasduetotheischemiaandwhichwasduetotheno-reflow.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE户使⽤本产品发表的科研⽂献•Metabolites.2022,12(10),956.•JInorgBiochem.2022Jan24;230:111733.•BiochemBiophysResCommun.2022Feb8;600:35-43.•ExpTherMed.November25,2021.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].KongLD,etal.InhibitionofMAOAandBbysomeplant-derivedalkaloids,phenolsandanthraquinones.JEthnopharmacol.2004Apr;91(2-3):351-5.[2].MaL,etal.PaeonolProtectsRatHeartbyImprovingRegionalBloodPerfusionduringNo-Reflow.FrontPhysiol.2016Jul21;7:298.McePdfH